Thesis Chemistry, which helps pharmaceutical companies with drug development, is planning to raise $2 million in capital, according to a regulatory filing.
Though the company indicated in the document that it’s yet to sell any amount of the offering, it also noted that “purchase agreements for $300,000 in securities have been received.”
Thesis has a U.S. headquarters in Mentor, Ohio and also maintains an office in the Canadian province of Ontario.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A company official didn’t return a call. Prior to this regulatory filing, Thesis had never filed a document with the U.S. Securities and Exchange Commission.
Thesis works with customers in the chemical and pharmaceutical industries. The services it offers include custom preparation, analysis and separation, manufacturing and consumer-scale production. The company’s promise to customers is “to help advance your next small molecule from concept to commercialization.”
At least some, though not all, of Thesis’ business operations appear to be similar to those of clinical research organizations.
